Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00431340
Status:
TERMINATED
Last Update Posted:
2015-07-08
First Post:
2007-02-02
Brief Title:
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed Refractory Multiple Myeloma
Sponsor:
Valerio Therapeutics
Organization:
Valerio Therapeutics
Study Overview
Official Title:
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed Refractory Multiple Myeloma
Status:
TERMINATED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated due to dose limiting toxicity
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label study will assess anti-tumor activity and safety of belinostat in combination with bortezomib Velcade in multiple myeloma patients refractory to or relapsed from at least one prior bortezomib-containing regimen Subjects will be administered both PXD101 and bortezomib on the same days ie days 1 4 8 and 11 of a 3-week cycle for up to 8 cycles
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None